SAN FRANCISCO--(BUSINESS WIRE)--Recent developments in biopharmaceutical R&D indicate that blockbuster drugs alone will not be sufficient to drive revenue growth. With big pharma discovering fewer and fewer new medicines in their own labs and major product failures occurring in late stage development, large companies have been pushed to search for more innovative strategies for growing and managing a sustainable pipeline.
